Table 2.
Chemotherapy regimens and responses of patients with advanced gastric cancer
| Characteristics | Total | Early WT | Elective WT | P value |
| No. | 110 | 46 | 64 | |
| Chemotherapy; combination | 76, 70% | 27, 59% | 49, 78% | 0.0371 |
| Agents | ||||
| 5-FU | 104 | 40, 85% | 64, 93% | 0.3532 |
| Platinum | 79 | 26, 55% | 53, 77% | 0.0100 |
| Irinotecan | 1 | 1, 2.1% | 0, 0% | 1.0000 |
| Taxane | 14 | 8, 17% | 6, 8.7% | 0.2460 |
| Trastuzumab | 19 | 9, 19% | 10, 14% | 0.6110 |
| Ramucirumab | 1 | 0, 0% | 1, 1.5% | 0.4072 |
| Response to first-line chemotherapy | ||||
| CR | 1, 0.91% | 0, 0% | 1, 1.6% | 0.1721 |
| PR | 23, 20.9% | 7, 15.2% | 16, 25% | |
| SD | 47, 42.7% | 17, 37.0% | 30, 46.9% | |
| PD | 16, 14.6% | 10, 21.7% | 6, 9.4% | |
| NE | 23, 20.9% | 12, 26.1% | 11, 17.2% | |
| RR | 24, 21.8% | 7, 15.2% | 17, 26.6% | |
| DCR | 71,64.5% | 24, 52.8% | 47, 73.5% | |
| Second-line chemotherapy, yes1 | 54, 63.5% | 24, 58.5% | 30, 68.2% | 0.3770 |
1
Twenty-five patients were not evaluated (during first-line chemotherapy). WT: Waiting time; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluated; RR: Response rate; DCR: Disease control rate.